Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

The present invention relates to a novel strain of Lactobacillus fermentum LM1016 deposited with the Korean Culture Center of Microorganisms under accession number KCCM12468P. The novel strain of the present invention has an effect of treating or preventing cardiovascular diseases, obesity, fatty liver or diabetes mellitus.

The present invention relates to a composition comprising the strain, and the composition may be used in a pharmaceutical product, a health functional food, a dairy product, a fermented product, a food additive and an animal feed and the like.

The present invention relates to a novel strain of Lactobacillus fermentum LM1016 deposited with the Korean Culture Center of Microorganisms under accession number KCCM12468P. The novel strain of the present invention has an effect of treating or preventing cardiovascular diseases, obesity, fatty liver or diabetes mellitus.

The present invention relates to a composition comprising the strain, and the composition may be used in a pharmaceutical product, a health functional food, a dairy product, a fermented product, a food additive and an animal feed and the like.

Embodiments of the invention are related generally to compositions comprising Co-Q10, a source of omega-3 fatty acids, and vitamin D, and methods of making thereof. In particular, the invention relates to stable compositions comprising Co-Q10, krill oil, vitamin D, and an antioxidant suitable for use as dietary supplements, and methods of making thereof. The compositions may further comprise an emulsifier to impart stability to the compositions.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

A composition, including fatty acids, egg yolk and an acidic aqueous medium, that includes at least 20 percent DHA by weight (20 wt %). An oil in water emulsion is provided, such as a mayonnaise, paste or has a mayonnaise-like consistency, for example suitable to be pressed or squeezed from a flexible container or tube. Methods are provided for treating disease in which DHA is deficient, for example sickle cell disease, and a medical food product including the composition and a process for the preparation of a composition or medical food product.

A composition, including fatty acids, egg yolk and an acidic aqueous medium, that includes at least 20 percent DHA by weight (20 wt %). An oil in water emulsion is provided, such as a mayonnaise, paste or has a mayonnaise-like consistency, for example suitable to be pressed or squeezed from a flexible container or tube. Methods are provided for treating disease in which DHA is deficient, for example sickle cell disease, and a medical food product including the composition and a process for the preparation of a composition or medical food product.

The present invention provides compositions and methods for enhancing the health of a subject by, for example, restoring the subjects gut microbiome, increasing water and electrolyte absorption in the digestive tract, and/or providing a therapeutic substance to the subject. In certain specific embodiments, the present invention can be used for ameliorating the adverse physiological effects that can result from the presence of one or more detrimental microorganisms in a subjects gut. In certain specific embodiments, the present invention can also be used as an enhanced mode of hydration or re-hydration, particularly for subjects suffering from, for example, a condition that causes vomiting and/or diarrhea.

The present invention provides compositions and methods for enhancing the health of a subject by, for example, restoring the subjects gut microbiome, increasing water and electrolyte absorption in the digestive tract, and/or providing a therapeutic substance to the subject. In certain specific embodiments, the present invention can be used for ameliorating the adverse physiological effects that can result from the presence of one or more detrimental microorganisms in a subjects gut. In certain specific embodiments, the present invention can also be used as an enhanced mode of hydration or re-hydration, particularly for subjects suffering from, for example, a condition that causes vomiting and/or diarrhea.